Onivyde FDA Approval History
FDA Approved: Yes (First approved October 22, 2015)
Brand name: Onivyde
Generic name: irinotecan liposomal
Dosage form: Injection
Previous Name: MM-398
Company: Merrimack Pharmaceuticals, Inc.
Treatment for: Pancreatic Cancer
Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan indicated for the treatment of post-gemcitabine metastatic adenocarcinoma of the pancreas.
Development Timeline for Onivyde
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.